Europe Diabetic Retinopathy Market Size, Share & Industry Trends Analysis Report By Type (Proliferative and Diabetic Macular Edema (DME)), By Treatment Type, By Country and Growth Forecast, 2021 - 2027

Europe Diabetic Retinopathy Market Size, Share & Industry Trends Analysis Report By Type (Proliferative and Diabetic Macular Edema (DME)), By Treatment Type, By Country and Growth Forecast, 2021 - 2027

The Europe Diabetic Retinopathy Market would witness market growth of 10.9% CAGR during the forecast period (2021-2027).

The availability of favorable reimbursement policies for ophthalmologic surgeries can boost the diabetic retinopathy market. Diabetic retinopathy is a progressive chronic eye disease that is majorly prevalent in geriatric people. Laser surgery not only helps to preserve vision, but it also helps to avoid further damage from proliferative diabetic retinopathy. Because of rapid advancements in the technologies that are used in the treatment of these disorders, elderly people and those in emerging economies are facing economic concerns as the cost of surgery rises. As a result, insurance providers like Medicaid and Medicare enact a number of policies aimed at lowering procedural costs, which helps the business flourish.

Technological improvements in ophthalmic diagnostic and surgical devices would accelerate the growth of the diabetic retinopathy market in the coming years. Optical coherence tomography along with other technologically advanced diagnostic technologies produces better cross-sectional images, allowing doctors to make better conclusions. Additionally, surgical instruments are more precise, which increases operation success rates. As a result, the availability of such improved ophthalmic instruments and devices has made diagnostic and surgical operations easier, which has benefited the industry's growth.

The diabetic retinopathy market in the region is estimated to grow significantly throughout the forecasting period due to the improving healthcare infrastructure along with advantageous reimbursement framework in developed European countries. Additionally, the prevalence of substantial medical requirements in expanding Eastern European economies, due to which, the regional market players are significantly increasing their efforts in order to fulfill these unmet demands of the population. Moreover, the rapidly increasing healthcare infrastructure of the region would enable healthcare practitioners to more effectively treat various disorders, including diabetic retinopathy, in people.

Further, in this region, the occurrence of diabetic retinopathy is found much higher in the patients who were suffering from type-II diabetes. According to the data shared by the National Library of Medicines, 3% to 4% of the people across Europe were affected with diabetic retinopathy in 2013

The Germany market dominated the Europe Diabetic Retinopathy Market by Country in 2020, and would continue to be a dominant market till 2027; thereby, achieving a market value of $546 Million by 2027. The UK market is exhibiting a CAGR of 10% during (2021 - 2027). Additionally, The France market would display a CAGR of 11.7% during (2021 - 2027).

Based on Type, the market is segmented into Proliferative and Diabetic Macular Edema (DME). Based on Treatment Type, the market is segmented into Anti VEGF Drug, Steroid Implants, Laser Surgeries, and Vitrectomy. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Allergan PLC (Abbvie, Inc.), Bayer AG, Alimera Sciences, Inc., Novartis AG, Pfizer, Inc., F-Hoffmann-La Roche Ltd., Ampio Pharmaceuticals-us, KOWA CO., LTD., Regeneron Pharmaceuticals, Inc., and Bausch Health Companies, Inc.

Scope of the Study

Market Segments covered in the Report:

By Type

  • Proliferative
  • Diabetic Macular Edema (DME)
By Treatment Type
  • Anti VEGF Drug
  • Steroid Implants
  • Laser Surgeries
  • Vitrectomy
By Country
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
Companies Profiled
  • Allergan PLC (Abbvie, Inc.)
  • Bayer AG
  • Alimera Sciences, Inc.
  • Novartis AG
  • Pfizer, Inc.
  • F-Hoffmann-La Roche Ltd.
  • Ampio Pharmaceuticals-us
  • KOWA CO., LTD.
  • Regeneron Pharmaceuticals, Inc.
  • Bausch Health Companies, Inc.
Unique Offerings from KBV Research
  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free


Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Diabetic Retinopathy Market, by Type
1.4.2 Europe Diabetic Retinopathy Market, by Treatment Type
1.4.3 Europe Diabetic Retinopathy Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Strategies Deployed in Diabetic Retinopathy Market
Chapter 4. Europe Diabetic Retinopathy Market by Type
4.1 Europe Proliferative Market by Country
4.2 Europe Diabetic Macular Edema (DME) Market by Country
Chapter 5. Europe Diabetic Retinopathy Market by Treatment Type
5.1 Europe Anti VEGF Drug Market by Country
5.2 Europe Steroid Implants Market by Country
5.3 Europe Laser Surgeries Market by Country
5.4 Europe Vitrectomy Market by Country
Chapter 6. Europe Diabetic Retinopathy Market by Country
6.1 Germany Diabetic Retinopathy Market
6.1.1 Germany Diabetic Retinopathy Market by Type
6.1.2 Germany Diabetic Retinopathy Market by Treatment Type
6.2 UK Diabetic Retinopathy Market
6.2.1 UK Diabetic Retinopathy Market by Type
6.2.2 UK Diabetic Retinopathy Market by Treatment Type
6.3 France Diabetic Retinopathy Market
6.3.1 France Diabetic Retinopathy Market by Type
6.3.2 France Diabetic Retinopathy Market by Treatment Type
6.4 Russia Diabetic Retinopathy Market
6.4.1 Russia Diabetic Retinopathy Market by Type
6.4.2 Russia Diabetic Retinopathy Market by Treatment Type
6.5 Spain Diabetic Retinopathy Market
6.5.1 Spain Diabetic Retinopathy Market by Type
6.5.2 Spain Diabetic Retinopathy Market by Treatment Type
6.6 Italy Diabetic Retinopathy Market
6.6.1 Italy Diabetic Retinopathy Market by Type
6.6.2 Italy Diabetic Retinopathy Market by Treatment Type
6.7 Rest of Europe Diabetic Retinopathy Market
6.7.1 Rest of Europe Diabetic Retinopathy Market by Type
6.7.2 Rest of Europe Diabetic Retinopathy Market by Treatment Type
Chapter 7. Company Profiles
7.1 Alimera Sciences, Inc.
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Regional Analysis
7.1.4 Research & Development Expense
7.1.5 Recent strategies and developments:
7.1.5.1 Partnerships, Collaborations, and Agreements:
7.1.5.2 Geographical Expansions:
7.2 F. Hoffmann-La Roche Ltd.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental and Regional Analysis
7.2.4 Research & Development Expense
7.2.5 Recent strategies and developments:
7.2.5.1 Partnerships, Collaborations, and Agreements:
7.2.5.2 Approvals and Trials:
7.3 Bausch Health Companies, Inc.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental and Regional Analysis
7.3.4 Research & Development Expense
7.3.5 Recent strategies and developments:
7.3.5.1 Partnerships, Collaborations, and Agreements:
7.3.5.2 Approvals and Trials:
7.4 Bayer AG
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Research & Development Expense
7.4.5 Recent strategies and developments:
7.4.5.1 Approvals and Trials:
7.5 Pfizer, Inc.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Regional & Segmental Analysis
7.5.4 Research & Development Expense
7.6 Novartis AG
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expense
7.7 Allergan PLC (AbbVie, Inc.)
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Regional Analysis
7.7.4 Research & Development Expense
7.7.5 Recent strategies and developments:
7.7.5.1 Partnerships, Collaborations, and Agreements:
7.8 Regeneron Pharmaceuticals, Inc.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Research & Development Expense
7.8.3.1 Approvals and Trials:
7.9 Ampio Pharmaceuticals, Inc.
7.9.1 Company Overview
7.10. Kowa Company, Ltd.
7.10.1 Company Overview

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings